Hormonal
Stimulating de novo adipogenesis (adipocyte hyperplasia) in visceral white adipose tissue during caloric excess drives healthy tissue remodeling, maintaining insulin sensitivity and preventing metabolic syndrome.
Focus on where your body stores fat and how it handles it, not just the scale. Visceral fat accumulation and inability to create new fat cells (hyperplasia) are key drivers of metabolic disease. While you cannot directly 'choose' where fat goes, maintaining metabolic health through exercise and diet supports healthy adipose function. Avoid extreme caloric deficits that may overwhelm adipose expandability, leading to ectopic fat storage in organs.
stimulating adipogenesis in the setting of caloric excess can drive healthy WAT remodeling... intra-abdominal WAT depots accumulated smaller and more numerous fat cells and few proinflammatory macrophages, and maintained local insulin sensitivity.
Why this rating
Strong evidence from multiple transgenic mouse models (MuralChaser, Col6 KO, Adipoq transgenics) and human observational studies linking subcutaneous expansion to health.
Source
Contribution of adipogenesis to healthy adipose tissue expansion in obesity
Lavanya Vishvanath et al. · Journal of Clinical Investigation · 2019
DOI 10.1172/jci129191
More from this paper
- Subcutaneous white adipose tissue (WAT) expansion is metabolically protective, whereas preferential visceral WAT expansion is associated with increased risk for insulin resistance and metabolic syndrome.Strong
- Fibro-inflammatory progenitors (FIPs) in adipose tissue are anti-adipogenic and promote inflammation and fibrosis, contributing to unhealthy adipose remodeling.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →